Tailored drug dosing shows promise for rare blood disorder
NCT ID NCT04720261
First seen Feb 28, 2026 · Last updated May 13, 2026 · Updated 11 times
Summary
This study tested a personalized approach to treating acquired thrombotic thrombocytopenic purpura (aTTP), a rare and serious blood clotting disorder. Researchers gave 58 adults a drug called caplacizumab, with the dose adjusted based on regular monitoring of a key blood enzyme (ADAMTS13). The goal was to see if this tailored regimen could reduce the risk of death, treatment failure, or flare-ups within 30 days. The study was terminated early, but the approach aimed to improve control of the disease while minimizing unnecessary medication.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA, ACQUIRED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ah-Hp Hopital Saint Louis
Paris, 75010, France
-
Ap-Hm Hopital de La Conception
Marseille, 13005, France
-
Ap-Hp Hopital de Cochin
Paris, 75014, France
-
Ap-Hp Hopital de Necker
Paris, 75015, France
-
Ap-Hp Hopital de St Antoine
Paris, 75571, France
-
CHU CAEN
Caen, 14033, France
-
Ch Edouard Herriot
Lyon, 69003, France
-
Ch Valenciennes
Valenciennes, 59300, France
-
Chu Amiens
Amiens, 80054, France
-
Chu Angers
Angers, 49933, France
-
Chu Besancon
Besançon, 25030, France
-
Chu Bordeaux
Bordeaux, 33404, France
-
Chu Clermont-Ferrand
Clermont-Ferrand, 63003, France
-
Chu Lille
Lille, 59037, France
-
Chu Limoges
Limoges, 87042, France
-
Chu Montpellier
Montpellier, 34295, France
-
Chu Nancy
Nancy, 54035, France
-
Chu Nantes
Nantes, 44093, France
-
Chu Reims
Reims, 51092, France
-
Chu Rennes
Rennes, 35033, France
-
Chu Rouen
Rouen, 76031, France
-
Chu Tours
Tours, 37044, France
-
Fort de France
Fort-de-France, 97261, Martinique
-
Reunion Sud
Saint-Paul, 97448, France
Conditions
Explore the condition pages connected to this study.